Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Microbiomics Acquires Long-Read Microbial Sequencing Firm DNASense

NEW YORK – Danish microbiome profiling firm Clinical Microbiomics said Friday that it has acquired long-read microbial sequencing service company DNASense, also of Denmark.

Financial details of the deal were not disclosed.

Copenhagen-based Clinical Microbiomics said the purchase will expand its expertise and offering for new market segments, such as agriculture, industrial, and environmental ecosystems. In addition, the deal adds DNASense's long-read DNA and RNA sequencing workflows to the company's multiomics analysis technology portfolio.

"The partnership with DNASense expands our portfolio of services and opens up new segments beyond human microbiome," Manoj Dadlani, chief commercial officer and chairman of Clinical Microbiomics, said in a statement. "This will significantly expand our addressable market and support our ambition to stay the global innovation and service leader for the microbiome field."

The acquisition is the third major deal for Clinical Microbiomics within the last 18 months. Last October, the company merged with Germantown, Maryland-based microbiome contract research organization CosmosID, leading to the first microbiome service company with a global infrastructure of multiomics labs meeting good practice guidelines (GxP) standards, according to Clinical Microbiomics.

A year before that, Clinical Microbiomics acquired Danish metabolomics company MS-Omics for an undisclosed amount, adding metabolomics capabilities to the company.

Clinical Microbiomics said it will rebrand in the summer to reflect the joint vision of Clinical Microbiomics, MS-Omics, CosmosID, and DNASense, "marking the beginning of the next chapter for the company."